Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S602000, C424S401000
Reexamination Certificate
active
06852747
ABSTRACT:
The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
REFERENCES:
patent: 4526179 (1985-07-01), Salesky
patent: 4959393 (1990-09-01), Torihara et al.
patent: 5449518 (1995-09-01), Junin et al.
patent: 5508155 (1996-04-01), Marrese et al.
patent: 5580549 (1996-12-01), Fukuda et al.
patent: 6123959 (2000-09-01), Jones et al.
patent: 6132740 (2000-10-01), Hu
patent: 6159482 (2000-12-01), Tuloup et al.
patent: WO 9912474 (1999-03-01), None
patent: WO 0056702 (2000-09-01), None
J.A. Beavo, Physiol. Rev., 1995, pp 725-748, vol. 75.
T.L. Fink, et al., “Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)”, J. Biol. Chem., Dec. 3, 1999, pp 34,613-34,620, vol. 274, No. 49.
J Lim, et al., “Activation of the cAMP-specific Phosphodiesterase PDE4D3 by Phosphorylation” J. Biol. Chem., Jul. 9, 1999, pp 29677-19685, vol. 274, No. 28.
S.L.C. Jin, et al., “Characterization of the Structure of a Low Km, Rolipram-sensitive cAMP Phosphodiesterase”, J. Biol. Chem., Sep. 15, 1992, pp 18929-18939, vol. 267, No. 26.
T. Kovala, et al., “Recombinant Expression of a Type IV, cAMP-Specific Phosphodiesterase: Characterization and Structure-Function Studies of Deletion Mutants”, Biochem., 1997, pp 2968-2976, vol. 36.
T. Michaeli, et al., “Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of CAMP Phosphodiesterase-deficient Saccharomyces cereuisiae”, J. Biol. Chem., Jun. 15, 1993, pp 12925-12932, vol. 268, No. 17.
W.K. Sonnenburg, et al., “Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases”, J. Biol. Chem., Dec. 29, 1995, pp 30989-31000, vol. 270, No. 52.
Y Kenan, et al., “Functions of the N-terminal Region of Cyclic Nucleotide Phosphodiesterase 3 (PDE 3) Isoforms”, J. Biol. Chem., Apr. 21, 2000, pp 12331-12338, vol. 275, No. 16.
Wolfgang Baehr, et al. “Isolation and Characterization of cGMP Phosphodiesterase from Bovine Rod Outer Segments”, J. Biol. Chem., Nov. 25, 1979, pp 11669-11677, vol. 254, No. 22.
J. A. Beavo, et al., “Hydrolysis of Cyclic Guanosine and Adenosine 3',5'-Monophosphates by Rat and Bovine Tissues”, J. Biol. Chem., Nov. 10, 1970, pp 5649-5655, vol. 245, No. 21.
Timothy J. Bloom, et al., “Identification and Tissue-specific Expression of PDE7 Phosphodiesterase Splice Variants”, Proc. Natl. Acad. Sci. USA, Nov. 1996, pp 14188-14192, vol. 93.
Bernard K. K. Fung, et al., “Subunit Stoichiometry of Retinal Rod cGMP Phosphodiestrase”, Biochem., 1990, pp 2657-2664, vol. 29.
Clare Gardner, et al., “Cloning and Characterization of the Human adn Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide Phosphodiestrase”, Biochem. Biophys.Res. Commun., 2000, pp 186-192, vol. 272.
Ping Han, et al., Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart, J. Biol. Chem., Jun. 6, 1997, pp 16152-16157, vol. 272, No. 26.
Ralf Hoffmann, et al., Differential Distribution of Rat PDE-7 mRNA in Embryonic and Adult Rat Brain, Cell Biochem. Biophys., 1998, pp 103-113, vol. 28.
Michio Ichimura, et al., “A new Cyclic Nucleotide Phosphodiesterase Isozyme Expressed ion the T-Lymphocyte Cell Lines”, Biochem. Biophys. Res Commun., Jun. 30, 1993, vol. 193, No. 3.
Carolyn J. Smith, et al., “Hormone-sensitive Cyclic GMP-inhibited Cyclic AMP Phosphodiesterase in Rat Adipocytes”, J. Biol. Chem., Jul. 15, 1991, pp 13385-13390, vol. 266, No. 20.
Theodore J. Torphy, et al., “Biochemical Characterostocs and Cellular Regulation of Phosphodiesterase IV”, New Drugs in Allergy and Asthma, 1993, pp 51-71, Agents & Actions Suuplement vol. 43.
Genbank Accession No: U77880; Rattus norvegicus GI:1916748; Sep. 28, 2001.
Genbank Accession No: AJ251860Homo sapiensmRNA GI:8216982; May 24, 2000.
Genbank Accession No: LI2052Homo sapienscAMP GI:179892; Jul. 22, 1999.
Genbank Accession No: U68171 Mus musculus cycl GI:1549394; Sep. 18, 1996.
Genbank Accession No: U67932Homo sapienscAMP GI:2306763; Jul. 22, 1999.
Bradley Stuart E.
Collington Eric W.
Fyfe Matthew C.
Procter Martin J.
Sambrook Smith Colin P.
Anderson Rebecca
Goodman Roseanne
McKane Joseph K.
Pfizer Inc.
LandOfFree
Resorcinol derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Resorcinol derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Resorcinol derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3447047